Total trials
146
Active
29
Phase 3
6
Total enrollment
26,602
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Low anticoagulation dose of argatroban and enoxaparin during ECMO | — | — | — | — | — | 1 | |
| Standard anticoagulation dose of argatroban and enoxaparin during ECMO | — | — | — | — | — | 1 | |
| Optimal medication treatment in patients with cardiac resynchronization therapy | — | — | — | — | — | 1 |
Next readouts
- 2028-12-31
- 2029-09
Top conditions
- Sepsis7
- Acute Kidney Injury4
- Laryngopharyngeal Reflux4
- Multiple Sclerosis4
- Septic Shock4
- Extraesophageal Reflux4
- Nasal Obstruction3
- Major Abdominal Surgery3
Frequently asked questions about University Hospital Ostrava
- How many clinical trials does University Hospital Ostrava have on ClinicalTrials.gov?
- University Hospital Ostrava is listed as the lead sponsor on 146 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Ostrava's trials are in Phase 3?
- 6 of University Hospital Ostrava's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University Hospital Ostrava focus on?
- University Hospital Ostrava's most-studied conditions on ClinicalTrials.gov are Sepsis, Acute Kidney Injury, Laryngopharyngeal Reflux, Multiple Sclerosis, Septic Shock.
- When are University Hospital Ostrava's next clinical trial readouts?
- University Hospital Ostrava has 2 upcoming primary-completion readouts tracked here; the soonest is “AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation”, expected around 2028-12-31.